Literature DB >> 10639191

Prostatic involution in men taking finasteride is associated with elevated levels of insulin-like growth factor-binding proteins (IGFBPs)-2, -4, and -5 .

L N Thomas1, A S Wright, C B Lazier, P Cohen, R S Rittmaster.   

Abstract

BACKGROUND: Insulin-like growth factor-binding proteins (IGFBPs)-2, -4, and -5 are associated with upregulation of apoptosis in the ovary. The purpose of this study was to assess the roles of IGF-I and IGFBPs during involution of the prostate. Frozen and fixed tissue was collected by transurethral prostatectomy from Caucasian men, aged 52-82 years, scheduled for prostatectomy for benign prostatic hyperplasia, who took either placebo (n = 7) or the 5alpha-reductase inhibitor finasteride for 6 days to 6 years (n = 15) prior to surgery.
METHODS: Intraprostatic androgen levels were measured by radioimmunoassay. Tissues were immunostained for IGF-I and IGFBP-2, -3, -4, and -5, and staining was quantitated by computerized image analysis. Serial sections were stained for markers of apoptosis (TUNEL and tissue transglutaminase) and IGFBP-2, -4, or -5.
RESULTS: IGF-I staining was significantly decreased in the medium-term (18-43 days) treatment group and remained so for the duration of the study (P = 0.026). IGFBP-3 staining was unchanged in the early and medium-term treatment groups; however, a transient earlier rise in the level of this proapoptotic protein cannot be ruled out. The percentage of epithelial cell area staining positively for IGFBP-2 increased significantly, from 1.6 +/- 0.5 in the placebo group to 12.0 +/- 2.0 (P < 0.0001), and 7.6 +/- 1.9 (P = 0.003) in the short (6-13 days) and medium-term treatment groups, respectively. IGFBP-4 staining increased from 2.2 +/- 0.6 to 9.8 +/- 1.9 (P < 0.0001) and 7.4 +/- 1.2 (P = 0.004) in the short and medium-term groups, respectively, and IGFBP-5 staining increased from 0.2 +/- 0.1 to 3.8 +/- 2.0 (P = 0.004) in the medium-term group. The results from serial sections showed that IGFBP-2 and -4 costained with markers of apoptosis, while IGFBP-5 did not.
CONCLUSIONS: These results indicate that IGFBP-2, -4, and -5 are associated with prostatic involution. Because of the timing and distribution of expression, we hypothesize that IGFBP-2 and -4 have a role as signals for apoptosis, but that IGFBP-5 likely does not. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10639191     DOI: 10.1002/(sici)1097-0045(20000215)42:3<203::aid-pros6>3.0.co;2-y

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  9 in total

Review 1.  Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors:  Martin E Gleave; Toby Zellweger; Kim Chi; Hideaki Miyake; Satoshi Kiyama; Laura July; Simon Leung
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

Review 2.  Androgens and prostate cancer.

Authors:  Alan I So; Antonio Hurtado-Coll; Martin E Gleave
Journal:  World J Urol       Date:  2003-10-29       Impact factor: 4.226

Review 3.  Mechanisms of the development of androgen independence in prostate cancer.

Authors:  Alan So; Martin Gleave; Antonio Hurtado-Col; Colleen Nelson
Journal:  World J Urol       Date:  2005-01-27       Impact factor: 4.226

Review 4.  PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Authors:  Ming Jiang; Douglas W Strand; Omar E Franco; Peter E Clark; Simon W Hayward
Journal:  Differentiation       Date:  2011-06-08       Impact factor: 3.880

Review 5.  Controversies in clinical cancer dormancy.

Authors:  Jonathan W Uhr; Klaus Pantel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-11       Impact factor: 11.205

6.  Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.

Authors:  David J Degraff; Adam A Aguiar; Robert A Sikes
Journal:  Am J Transl Res       Date:  2009-01-20       Impact factor: 4.060

Review 7.  Growth factors in benign prostatic hyperplasia: basic science implications.

Authors:  M Scott Lucia; James R Lambert
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

Review 8.  Biological effects and regulation of IGFBP5 in breast cancer.

Authors:  Jürgen Dittmer
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-25       Impact factor: 6.055

Review 9.  Control of IGFBP-2 Expression by Steroids and Peptide Hormones in Vertebrates.

Authors:  Andreas Hoeflich; Elisa Wirthgen; Robert David; Carl Friedrich Classen; Marion Spitschak; Julia Brenmoehl
Journal:  Front Endocrinol (Lausanne)       Date:  2014-04-07       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.